Overview

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy and safety of camrelizumab combined with apatinib mesylate and nab-paclitaxel .
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital of Xiamen University
Treatments:
Apatinib
Paclitaxel